The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Concentrations of the potent, HIV(human immunodeficiency virus) inactivating protein, cyanovirin-N (CV-N), which completely inhibit HIV-1 infectivity, do not block the binding of soluble CD4-receptor (sCD4) to HIV-1 lysates nor the attachment of intact HIV-1 virions to several target T-cell lines. Furthermore, in contrast to the known disassociative effects of sCD4 on viral envelope glycoproteins, treatment of HIVRF with high concentrations of CV-N results in complete viral inactivation but without apparent shedding of gp120 or other ultrastructural changes. These results are consistent with the view that the virucidal effects of CV-N result from interference with step(s) in the fusion process subsequent to the initial binding of the virus to target cells.
Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick Cancer Research & Development Center, Maryland 21702-1201, USA.
J M
JM
Mariner
J B
JB
McMahon
B R
BR
O'Keefe
K
K
Nagashima
M R
MR
Boyd
D019380:Anti-HIV Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D015704:CD4 Antigens / Q000187:drug effects / Q000502:physiology*; D002352:Carrier Proteins / Q000494:pharmacology*; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D015699:HIV Envelope Protein gp120 / Q000187:drug effects / Q000502:physiology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D006801:Humans; D007700:Kinetics
D019380:Anti-HIV Agents; D001426:Bacterial Proteins; D015704:CD4 Antigens; D002352:Carrier Proteins; D015699:HIV Envelope Protein gp120; C107733:cyanovirin N